AD/PD 2024 | Neuroimaging and fluid biomarkers in early-onset Alzheimer’s disease

Melissa E Murray, PhD, Mayo Clinic, Jacksonville, FL, discusses updates on the study of neuroimaging and fluid biomarkers in individuals with early-onset Alzheimer’s disease (AD), acknowledging the ongoing progress needed in fluid biomarkers. A consistent finding across neuroimaging studies is increased pathology in younger individuals. Reasons for this could be more general, such as more cognitive reserve providing better disease resilience in younger individuals, or more specific molecular changes, such as impaired phagocytosis. Dr Murray notes the need for further research into fluid biomarkers and how they perform in early-onset AD compared to typical late-onset disease. This interview took place at the AP/DPD 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.